The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter prospective observational study of QoL after palliative surgery for patients with bowel obstruction caused by peritoneal dissemination of gastric cancer.
 
Yuichi Ito
No Relationships to Disclose
 
Kazumasa Fujitani
No Relationships to Disclose
 
Kentaro Sakamaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Genomic Health
 
Masahiko Ando
No Relationships to Disclose
 
Ryohei Kawabata
No Relationships to Disclose
 
Yutaka Tanizawa
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Takanobu Yamada
No Relationships to Disclose
 
Motohiro Hirao
No Relationships to Disclose
 
Makoto Yamada
No Relationships to Disclose
 
Jun Hihara
No Relationships to Disclose
 
Ryoji Fukushima
Research Funding - Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Choda
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MSD K.K; Olympus; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - abbott Japan (Inst); Abbvie (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Japan Blood Products Organization (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Maruho (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst)
 
Shin Teshima
No Relationships to Disclose
 
Hisashi Shinohara
No Relationships to Disclose
 
Masato Kondo
No Relationships to Disclose